Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard DiMarchi

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Cell Metabolism|October 9, 2014
Break on through to the other 1Alexei Kharitonenkov, Richard DiMarchi
Trends in Endocrinology and Metabolism: TEM|October 23, 2015
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal PropertiesAlexei Kharitonenkov, Richard DiMarchi
Endocrine Development|September 6, 2017
Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic ReceptorsNoushafarin Khajavi, Heike Biebermann, Matthias Tschöp, et al.
Organic Letters|November 5, 2016
Synthetic Route to Human Relaxin-2 via Iodine-Free Sequential Disulfide Bond FormationXu Yang, Vasily Gelfanov, Fa Liu, et al.
Vitamins and Hormones|August 23, 2005
Leptin: structure, function and biologyFaming Zhang, Yanyun Chen, Mark Heiman, et al.
Diabetes, Obesity & Metabolism|July 22, 2017
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitusChristophe Schmitt, Agnès Portron, Shirin Jadidi, et al.
Diabetes, Obesity & Metabolism|July 26, 2017
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjectsAgnès Portron, Shirin Jadidi, Neena Sarkar, et al.
Accounts of Chemical Research|August 4, 2017
Synthetic Advances in Insulin-like Peptides Enable Novel BioactivityFa Liu, Pengyun Li, Vasily Gelfanov, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2024
MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized TrialPatricia Carney, Gordon B Cutler, Kristi Schneider, et al.
Comprehensive Physiology|December 20, 2019
Gut Peptide Agonism in the Treatment of Obesity and DiabetesGerald Grandl, Aaron Novikoff, Richard DiMarchi, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Cell Metabolism|October 9, 2014
Break on through to the other 1Alexei Kharitonenkov, Richard DiMarchi
Trends in Endocrinology and Metabolism: TEM|October 23, 2015
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal PropertiesAlexei Kharitonenkov, Richard DiMarchi
Endocrine Development|September 6, 2017
Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic ReceptorsNoushafarin Khajavi, Heike Biebermann, Matthias Tschöp, et al.
Organic Letters|November 5, 2016
Synthetic Route to Human Relaxin-2 via Iodine-Free Sequential Disulfide Bond FormationXu Yang, Vasily Gelfanov, Fa Liu, et al.
Vitamins and Hormones|August 23, 2005
Leptin: structure, function and biologyFaming Zhang, Yanyun Chen, Mark Heiman, et al.
Diabetes, Obesity & Metabolism|July 22, 2017
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitusChristophe Schmitt, Agnès Portron, Shirin Jadidi, et al.
Diabetes, Obesity & Metabolism|July 26, 2017
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjectsAgnès Portron, Shirin Jadidi, Neena Sarkar, et al.
Accounts of Chemical Research|August 4, 2017
Synthetic Advances in Insulin-like Peptides Enable Novel BioactivityFa Liu, Pengyun Li, Vasily Gelfanov, et al.
The Journal of Clinical Endocrinology and Metabolism|November 22, 2024
MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized TrialPatricia Carney, Gordon B Cutler, Kristi Schneider, et al.
Comprehensive Physiology|December 20, 2019
Gut Peptide Agonism in the Treatment of Obesity and DiabetesGerald Grandl, Aaron Novikoff, Richard DiMarchi, et al.
Pageof 5